Roarlix 120mg Tablet

Roarlix 120mg Tablet

Prescription requiredRx Required

Salt Composition: Relugolix

Expiry Date: 01/2028

Special offer

Price on Request

Price on Request

Inclusive of all taxes

▼

30 Tablets in Bottle

About The Product

​Prostate Cancer​


Description

Roarlix 120mg tablet is an anti-cancer medication used under the prescription of a healthcare professional. It is used in the treatment of advanced prostate cancer in men by reducing the effect of male hormones that promote the growth of cancer cells, thereby slowing disease progression and improving symptom control.

Its active drug composition is Relugolix which belongs to the group of gonadotropin- releasing hormone (GnRH) receptor antagonists. It helps lower the testosterone levels quickly and effectively without causing an initial hormone surge.


Uses

  • Treat prostate cancer


Side Effects

  • Some medicines show side effects but it depends from person to person and based on the patient response to the treatment.
  • Roarlix 120mg tablet also causes various symptoms but they can be manageable with treatments.
  • Common ones include: • Tiredness • Constipation • Diarrhea • Dizziness • Headache • Nausea • Rash • Fatigue • low red cell count (anemia) • Breast enlargement in men (gynecomastia) • Hot flushes • Increased blood sugar levels • Increased blood fat (triglyceride) levels • Muscle and joint pain • Decreased blood hemoglobin levels • Increased liver enzymes

How To Use

  • Roarlix 120mg should be taken with or without food, exactly as prescribed by healthcare professional. Take it at the same time everyday to enhance the effectiveness of the treatment.
  • Do not crush, crew or break the tablet just swallow it whole with a glass of water. Proper medication dosage and duration is correctly administered by the healthcare professional to ensure safe and effective treatment.
    ​

How It Works

  • Roarlix 120mg tablet works by lowering the amount of testosterone hormone which is responsible for the production of cancer cells in the body. In this way, it slows or stops the spreading of cancer cells to other parts of the body.
  • It acts by directly blocking gonadotropin releasing hormone (GnRH) receptors in the pituitary gland which reduces the release of luteinizing hormone and ultimately suppresses testosterone production. It helps control tumor growth without causing an initial rise in testosterone level.

Safety Advice

Alcohol

Alcohol is prohibited while using Roarlix 120mg tablet as it can disrupt the kidney function thereby disturb the treatment. Doctor consultation is required while using the medication.

Pregnancy

It is unknown whether Roarlix 120mg tablet cause any side effects to pregnant women but its use should be avoided during pregnancy unless clearly advised by the healthcare professional.

Breast Feeding

Women who breastfeed their child should consult the doctor before using Roarlix 120mg tablet to ensure safety to the child and ensure the safe and effective treatment option.

Driving

Roarlix tablet may cause dizziness or weakness. Do not use medication while driving that require full alertness until you know how the medicine affects you.

Kidney

Roarlix 120mg tablet can interfere with the kidney function, kidney patients should avoid using this medication to ensure safe treatment.

Liver

Roarlix 120mg tablet can be taken under the doctor's prescription. Follow the recommended dosage as guided by the healthcare professional.

FAQs

Dosage and duration of Roarlix 120mg tablet depend on the patient medical history and response to the treatment.

References

  • Shore, N. D., Saad, F., Cookson, M. S., George, D. J., Saltzstein, D. R., Tutrone, R., ... & Tombal, B. (2020). Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. New England Journal of Medicine, 382(23), 2187-2196. https://pubmed.ncbi.nlm.nih.gov/32469183/
  • Shirley, M. (2023). Relugolix: a review in advanced prostate cancer. Targeted Oncology, 18(2), 295-302. https://pubmed.ncbi.nlm.nih.gov/36652173/
  • Spratt, D. E., George, D. J., Shore, N. D., Cookson, M. S., Saltzstein, D. R., Tutrone, R., ... & Tombal, B. F. (2024). Efficacy and safety of radiotherapy plus relugolix in men with localized or advanced prostate cancer. JAMA oncology, 10(5), 594-602. https://pubmed.ncbi.nlm.nih.gov/38451492/
  • Markham, A. (2019). Relugolix: first global approval. Drugs, 79(6), 675-679. https://pubmed.ncbi.nlm.nih.gov/30937733/
  • Saad, F., & Shore, N. D. (2021). Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer. Therapeutic Advances in Medical Oncology, 13, 1758835921998586. https://pubmed.ncbi.nlm.nih.gov/34408793/​

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Read full medical disclaimer in Terms & Conditions
Magicine PharmacopyCopyright 2026